Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference - 07/08/11
Abstract |
Background |
Methotrexate remains a valuable option for the treatment of psoriasis. This report will summarize studies regarding the use of methotrexate since the last guidelines were published in 1998.
Objective |
A task force of the National Psoriasis Foundation Medical Board was convened to evaluate treatment options. Our aim was to achieve a consensus on new updated guidelines for the use of methotrexate in the treatment of psoriasis.
Methods |
Reports in the literature were reviewed regarding methotrexate therapy.
Results |
A consensus was achieved on use of methotrexate in psoriasis including specific recommendations on dosing and monitoring. The consensus received unanimous approval from members of the Medical Board of the National Psoriasis Foundation.
Limitations |
There are few evidence-based studies on the treatment of psoriasis with methotrexate. Many of the reviewed reports are for the treatment of rheumatoid arthritis.
Conclusions |
Methotrexate is a safe and effective drug for the treatment of psoriasis. Appropriate patient selection and monitoring will significantly decrease the risks of side effects. In patients without risk factors for hepatic fibrosis, liver biopsies may not be indicated or the frequency of liver biopsies may be markedly reduced.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ACR, ALT, AST, CDC, FDA, NASH, NSAID, PASI, PIIINP, PPD, PUVA
Plan
Members of the Medical Advisory Board of the National Psoriasis Foundation are listed in the Appendix. |
|
Funding sources: None. |
|
Dr Kalb has received consulting fees or served as an investigator for Abbott, Amgen, Astellas, Centocor, Genentech, Stiefel, and Warner/Chilcott. Dr Strober has been a speaker, advisor, consultant, and/or investigator for Abbott, Amgen, Astellas, Genentech, Centocor, and Wyeth. Dr Weinstein has been an investigator for Abbott Labs, Amgen, Genentech, and Centocor. Dr Lebwohl has received consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Astellas, Centocor, Genentech, Stiefel and Novartis. |
Vol 60 - N° 5
P. 824-837 - mai 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?